Loading...
XETR
AAQ1
Market cap16mUSD
Apr 09, Last price  
1.65EUR
1D
0.00%
1Q
-3.51%
Jan 2017
-85.05%
Name

Aap Implantate AG

Chart & Performance

D1W1MN
XETR:AAQ1 chart
No data to show
P/E
—
P/S
1.29
EPS
—
Div Yield, %
—
Shrs. gr., 5y
21.55%
Rev. gr., 5y
1.26%
Revenues
11m
-0.33%
11,358,25014,250,000028,006,00031,884,00033,101,00028,440,00029,205,00036,414,00027,672,00030,414,00012,280,00010,486,00010,902,00010,781,00011,739,0009,326,00012,166,00011,516,00011,478,000
Net income
-5m
L+99.88%
-139,664655,00001,511,000-5,234,0001,938,00051,000395,0002,410,000-2,454,000-456,000-5,292,00014,629,000-9,271,000-7,666,000-19,439,000-8,937,000-2,522,000-2,564,000-5,125,000
CFO
-3m
L+58.06%
-2,133,000718,0001,729,000-299,000544,0004,761,0002,654,0003,213,0007,088,0003,547,000-2,945,000-2,265,000-7,203,000-5,428,000-5,919,000-5,767,000-3,675,000-2,470,000-1,893,000-2,992,000

Profile

aap Implantate AG, a medical device company, develops, manufactures, and markets trauma products for orthopedics in Germany, the United States, and internationally. It offers LOQTEQ, an anatomical plating system for fracture treatment; and a range of cannulated screws, standard plates, and screws. The company sells its products directly to hospitals, buying syndicates, and hospital groups, as well as through a network of distributors under the aap brand name. aap Implantate AG was founded in 1990 and is headquartered in Berlin, Germany.
URL
https://www.aap.de/
IPO date
May 10, 1999
Employees
111
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
11,478
-0.33%
11,516
-5.34%
Cost of revenue
6,709
5,422
Unusual Expense (Income)
NOPBT
4,769
6,094
NOPBT Margin
41.55%
52.92%
Operating Taxes
(87)
(1,049)
Tax Rate
NOPAT
4,856
7,143
Net income
(5,125)
99.88%
(2,564)
1.67%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,291
1,186
BB yield
Debt
Debt current
1,824
2,004
Long-term debt
5,410
4,053
Deferred revenue
Other long-term liabilities
299
475
Net debt
5,621
5,485
Cash flow
Cash from operating activities
(2,992)
(1,893)
CAPEX
(405)
(485)
Cash from investing activities
(397)
(469)
Cash from financing activities
4,422
475
FCF
5,750
8,464
Balance
Cash
1,640
504
Long term investments
(27)
68
Excess cash
1,039
Stockholders' equity
(52,769)
(13,138)
Invested Capital
69,207
29,491
ROIC
9.84%
23.70%
ROCE
28.77%
36.95%
EV
Common stock shares outstanding
8,295
5,956
Price
Market cap
EV
EBITDA
6,383
7,767
EV/EBITDA
Interest
166
372
Interest/NOPBT
3.48%
6.10%